Healthcare [ 3/11 ] | Drug Manufacturers—Specialty & Generic [ 23/154 ]
US | NASDAQ | Stock
Reported Date | EPSChange YoY | EstimateSurprise |
---|---|---|
Nov 7, 22 | -0.53
Decreased by
-165.00%
|
-0.44
Decreased by
-20.45%
|
Aug 11, 22 | -2.71
Decreased by
-1.25 K%
|
-3.70
Increased by
+26.76%
|
Mar 30, 22 | -0.20
Increased by
0.00%
|
-0.15
Decreased by
-33.33%
|
Nov 2, 21 | -0.18
Increased by
0.00%
|
-0.19
Increased by
+5.26%
|
Jul 26, 21 | -0.20
Decreased by
-66.67%
|
-0.22
Increased by
+9.09%
|
May 4, 21 | -0.20
Decreased by
-100.00%
|
-0.21
Increased by
+4.76%
|
Mar 1, 21 | -0.20
Decreased by
-100.00%
|
-0.22
Increased by
+9.09%
|
Nov 12, 20 | -0.18
Decreased by
-125.00%
|
-0.18 |
Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
---|---|---|---|
Sep 30, 22 | 3.00 M
Increased by
+133.26%
|
-19.67 M
Decreased by
-17.25%
|
Decreased by
-655.10%
Increased by
+49.73%
|
Jun 30, 22 | 2.13 M
Increased by
+79.41%
|
-12.22 M
Increased by
+30.72%
|
Decreased by
-574.74%
Increased by
+61.38%
|
Mar 31, 22 | 1.76 M
Increased by
+1.42 K%
|
-11.77 M
Increased by
+31.29%
|
Decreased by
-668.31%
Increased by
+95.47%
|
Dec 31, 21 | 1.51 M
Increased by
+102.00%
|
-23.36 M
Decreased by
-32.56%
|
Decreased by
-1.54 K%
Increased by
+34.38%
|
Sep 30, 21 | 1.29 M
Increased by
+N/A%
|
-16.77 M
Decreased by
-8.04%
|
Decreased by
-1.30 K%
Decreased by
N/A%
|
Jun 30, 21 | 1.19 M
Increased by
+N/A%
|
-17.64 M
Decreased by
-62.91%
|
Decreased by
-1.49 K%
Decreased by
N/A%
|
Mar 31, 21 | 116.00 K
Increased by
+N/A%
|
-17.13 M
Decreased by
-117.28%
|
Decreased by
-14.77 K%
Decreased by
N/A%
|
Dec 31, 20 | 749.00 K
Increased by
+N/A%
|
-17.62 M
Decreased by
-192.64%
|
Decreased by
-2.35 K%
Decreased by
N/A%
|
Rank | ETF | Shares | Market Value | Weight % in ETF |
---|
Agile Therapeutics, Inc., a women's healthcare company, researches, develops, and commercializes prescription contraceptive products for women in the United States. Its lead product is Twirla, also known as AG200-15, a once-weekly prescription combination hormonal contraceptive patch. The company is also developing a pipeline of Twirla line extensions and other products, including AG200-15 Extended Regimen (ER), a regimen that allows a woman to have four episodes of withdrawal bleeding per year; AG200-15 smaller patch (SmP), which is a regimen designed to provide shorter and lighter withdrawal bleeds, and enhance contraceptive efficacy; AG200-15 ER SmP, a regimen to allow a woman to extend the length of her contraceptive cycle, as well as have shorter and lighter withdrawal bleeding episodes per year; and P-Patch, a progestin-only contraceptive patch intended for use by women who are unable or unwilling to take estrogen. Agile Therapeutics, Inc. was incorporated in 1997 and is headquartered in Princeton, New Jersey.